DCM
CNTX icon

Difesa Capital Management’s Context Therapeutics CNTX Stock Holding History

Difesa Capital Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-34,878
Closed -$55.8K – 9
2023
Q2 		$55.8K Hold
34,878
– – 0.15% 28
2023
Q1 		$19.6K Hold
34,878
– – 0.01% 107
2022
Q4 		$22.7K Hold
34,878
– – 0.02% 113
2022
Q3 		$39K Hold
34,878
– – 0.02% 128
2022
Q2 		$74K Buy
+34,878
New +$65.4K 0.04% 123

Other funds holding CNTX

ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CHAM
Clear Harbor Asset Management Stamford, Connecticut $1.45B AUM 23.7% 1-Year Est. Return

Difesa Capital Management's CNTX Position: Q3 2023 in Review

Difesa Capital Management sold out of Context Therapeutics (CNTX) in Q3 2023, closing a stake of 34,878 shares — an estimated $55.8K sold.

Difesa Capital Management first reported a position in CNTX in Q2 2022 and held it in 5 quarters. The position peaked at $74K in Q2 2022. 23 funds tracked by Wall St. Rank hold CNTX as of Q3 2023.

  • Difesa Capital Management reported no remaining Context Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Difesa Capital Management sold 34,878 Context Therapeutics shares in Q3 2023, an estimated $55.8K.
  • Difesa Capital Management first reported a position in Context Therapeutics in Q2 2022 and held it in 5 quarters.
  • Difesa Capital Management's Context Therapeutics position peaked at $74K in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2023.

Based on Difesa Capital Management's 13F filing for Q3 2023.